Ocular Hypertension Articles & Analysis
9 news found
The SIGHT-1 study demonstrated the safety and tolerability of the company’s lead asset, LL-BMT1, a weekly medicated contact lens releasing bimatoprost to treat open angle glaucoma and ocular hypertension. The poster also delves into the improved dryness scores observed over the seven-day wear period as well as the efficacy signals seen in the study. ...
The team showcased the four lead programmes and highlighted significant progress towards identifying candidate gene constructs for diabetic macular oedema, wet-form, neovascular age-related macular degeneration, geographic atrophy and ocular hypertension. The company expects to complete pre-clinical proof-of-concept studies by 3Q 2022 for diabetic macular oedema ...
ByIkarovec
That study demonstrated the safety and tolerability of the Company’s lead asset, LL-BMT1, a weekly medicated contact lens releasing bimatoprost to treat open angle glaucoma and ocular hypertension. The study also saw a positive efficacy signal leading the Company to advance to a dose escalating Phase 2b clinical trial that is planned for 2022. ...
The Phase 3 program consists of two prospective, randomized, double-masked clinical trials designed to compare the safety and efficacy ofiDose TRto topical timolol ophthalmic solution, 0.5%, in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension. The primary efficacy endpoint of the Phase 3 studies is ...
Dan Myers, the company’s CEO, was selected to present the successful Phase 2a data from the Company’s first in-human clinical study SIGHT-1 (Sustained Innovative Glaucoma and ocular Hypertension Treatment) with LLT-BMT1, a drug-eluting contact lens to treat mild to moderate glaucoma and ocular hypertension. ...
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the successful completion of the first study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating mild to moderate glaucoma and ...
Leo Lens expanded its SAB with four eye care practitioners who are highly experienced in the glaucoma field as the company prepares for its first human clinical trial with its lead asset to treat glaucoma and ocular hypertension. The expanded SAB will provide independent scientific review and guidance to the Company with regards to its R&D activities and ...
This product is designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). LL-BMT1 is a novel product intended to continuously deliver bimatoprost, even while sleeping, to treat OAG and OHT. ...
” According to Gus Gazzard, MBBChir MA MD FRCOphth, director of the Glaucoma Service at the prestigious Moorfields Eye Hospital, professor in ophthalmology, glaucoma studies at UCL London, a consultant ophthalmic surgeon (glaucoma and cataract) and chief investigator of the Laser in Glaucoma and Ocular Hypertension Trial (LiGHT), and the leading European ...